Compare Immunovant Inc. Common Stock (IMVT) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs MakeMyTrip Ltd — how do they compare? Immunovant Inc. Common Stock trades at $30.34 (market cap $6.25B), while MakeMyTrip Ltd trades at $44.2 (market cap $4.09B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and MakeMyTrip Ltd for 12 Days on average.
| IMVT | MMYT | |
|---|---|---|
Market Cap | $6.25B | $4.09B |
Volume | 1,755,411 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $94.43 |
52-Week Low | $17.03 | $36.30 |
Typical Hold Time | 1 Days | 12 Days |
Enterprise Value | $5.35B | $4.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MMYT trades at $44.06, up 1.5% with bearish technical signals but strong analyst support. The company reported $978M revenue and $95M net income for 2025, though earnings have been mixed with two recent misses. Valuation metrics show high P/E of 189 but solid gross margins of 73%. Technical indicators show oversold conditions with RSI at 25.31, while institutional sentiment remains positive with 72.7% buy ratings and $77 consensus target.
The stock presents a divergence between technical weakness and fundamental optimism. Upside potential exists from the 75% analyst price target premium and planned Indian listing, but risks include volatile earnings performance, rising debt-to-asset ratio projection to 79.9%, and competitive travel sector pressures. Current levels near support at $42-43 may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
